These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2466330)

  • 21. Background Knowledge and Attitude of Pregnant Women towards Ultrasound Screening at 20-23 Weeks Gestation.
    Salmoukas C; Kundu S; Soergel P; Hillemanns P; von Kaisenberg C; Staboulidou I
    Z Geburtshilfe Neonatol; 2016 Feb; 220(1):16-20. PubMed ID: 26039497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results and views of women in population-wide pregnancy screening for trisomy 21 in east Finland.
    Heikkilä A; Ryynänen M; Kirkinen P; Saarikoski S
    Fetal Diagn Ther; 1997; 12(2):93-6. PubMed ID: 9218949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of maternal serum alpha-fetoprotein screening on antenatal diagnosis.
    Brock DJ
    Br Med J (Clin Res Ed); 1982 Jul; 285(6338):365-7. PubMed ID: 6178461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attitudes toward maternal serum screening in Chinese women with positive results.
    Jan SW; Chen CP; Huang LH; Huang FY; Lan CC
    J Genet Couns; 1996 Dec; 5(4):169-80. PubMed ID: 11655115
    [No Abstract]   [Full Text] [Related]  

  • 25. Results and benefits of a maternal serum alpha-fetoprotein screening program.
    Milunsky A; Alpert E
    JAMA; 1984 Sep; 252(11):1438-42. PubMed ID: 6206249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ethnicity, bioethics, and prenatal diagnosis: the amniocentesis decisions of Mexican-origin women and their partners.
    Browner CH; Preloran HM; Cox SJ
    Am J Public Health; 1999 Nov; 89(11):1658-66. PubMed ID: 10553385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Routine assessment of amniotic fluid alpha-Fetoprotein in early second-trimester amniocentesis is no longer justified.
    Widlund KF; Gottvall T
    Acta Obstet Gynecol Scand; 2007; 86(2):167-71. PubMed ID: 17364279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survey on knowledge, attitude, acceptance and related factors among pregnant women in Thailand regarding antenatal thalassaemia screening.
    Hanprasertpong T; Raungrongmorakot K; Geater A; Puapornpong P; Laosooksathit W; Hemachandra A; Suksamarnwong M
    J Obstet Gynaecol; 2018 Oct; 38(7):950-955. PubMed ID: 29565194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 'Collective fictions': similarities in reasons for accepting maternal serum alpha-fetoprotein screening among women of diverse ethnic and social class backgrounds.
    Press NA; Browner CH
    Fetal Diagn Ther; 1993 Apr; 8(Suppl. 1):97-106. PubMed ID: 11653028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obstetrical complications associated with abnormal maternal serum markers analytes.
    Gagnon A; Wilson RD;
    J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amniotic-fluid alpha-fetoprotein measurement in antenatal diagnosis of anencephaly and open spina bifida in early pregnancy. Second report of the U.K. Collaborative Study on Alpha-fetoprotein in Relation to Neural-tube Defects.
    Lancet; 1979 Sep; 2(8144):651-62. PubMed ID: 90757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maternal serum alpha-fetoprotein as screening test for Down syndrome.
    Brock DJ
    Lancet; 1984 Jun; 1(8389):1292. PubMed ID: 6202996
    [No Abstract]   [Full Text] [Related]  

  • 33. Antenatal screening for congenital nephrosis in Finland by maternal serum alpha-fetoprotein.
    Ryynänen M; Seppälä M; Kuusela P; Rapola J; Aula P; Seppä A; Jokela V; Castren O
    Br J Obstet Gynaecol; 1983 May; 90(5):437-42. PubMed ID: 6189511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Presenting a routine screening test in antenatal care: practice observed.
    Marteau TM; Slack J; Kidd J; Shaw RW
    Public Health; 1992 Mar; 106(2):131-41. PubMed ID: 1376931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maternal serum AFP screening.
    Milunsky A; Alpert E
    N Engl J Med; 1978 Mar; 298(13):738-9. PubMed ID: 75505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of education on physicians' knowledge of a laboratory test: the case of maternal serum alpha-fetoprotein screening.
    Holtzman NA; Faden RR; Leonard CO; Chase GA; Ulrich SR
    J Clin Ethics; 1991; 2(4):243-7; discussion 247-50. PubMed ID: 1725136
    [No Abstract]   [Full Text] [Related]  

  • 37. Carrier screening for cystic fibrosis: a pilot study of the attitudes of pregnant women.
    Botkin JR; Alemagno S
    Am J Public Health; 1992 May; 82(5):723-5. PubMed ID: 1566951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Alpha-1-fetoprotein screening--development and problems].
    Grob PJ
    Soz Praventivmed; 1981 Sep; 26(4):217-20. PubMed ID: 6171116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Women's decision-making in prenatal screening.
    Santalahti P; Hemminki E; Latikka AM; Ryynänen M
    Soc Sci Med; 1998 Apr; 46(8):1067-76. PubMed ID: 9579758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prenatal diagnosis of neural tube defects. VIII. The importance of serum alpha-fetoprotein screening in diabetic pregnant women.
    Milunsky A; Alpert E; Kitzmiller JL; Younger MD; Neff RK
    Am J Obstet Gynecol; 1982 Apr; 142(8):1030-2. PubMed ID: 6176126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.